Acetylsalicylic acid, diclofenac, and lornoxicam, but not rofecoxib, affect platelet CD 62 expression

被引:17
作者
Blaicher, AM
Landsteiner, HT
Al-Falaki, O
Zwerina, J
Volf, I
Gruber, D
Zimpfer, M
Hoerauf, K
机构
[1] Univ Vienna, Dept Med Stat, Vienna, Austria
[2] Univ Vienna, Inst Med Physiol, Vienna, Austria
[3] Univ Vienna, Ludwig Boltzmann Inst Clin Anesthesiol & Intens C, Vienna, Austria
[4] Univ Vienna, Dept Anesthesiol & Gen Intens Care, Vienna, Austria
关键词
D O I
10.1213/01.ANE.0000105866.99259.94
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Nonsteroidal antiinflammatory drugs are routinely administered in the perioperative period. Because of the absence of cyclooxygenase-2 in platelets, cyclooxygenase-2-selective drugs are thought not to cause platelet inhibition. Because platelets play an important role in the coagulation process, the absence of platelet function inhibition may lead to fewer bleeding complications after surgery. We studied the influence of aspirin, diclofenac, lornoxicam, and rofecoxib on arachidonic acid and collagen-induced CD 62 P (P selectin) expression by using flow cytometry. Blood from 68 volunteers was obtained before and 1, 3, and 12 h after the oral ingestion of 1 of the randomly assigned study medications. Aspirin, diclofenac, and lornoxicam had a significant effect on arachidonic acid and collagen-induced CD 62 P expression in platelets, whereas rofecoxib did not show this effect. We conclude that rofecoxib is safe to use perioperatively with respect to inhibition of platelet function.
引用
收藏
页码:1082 / 1085
页数:4
相关论文
共 18 条
[11]  
Kenny G N, 1992, Drugs, V44 Suppl 5, P31
[12]   SELECTIVE-INHIBITION OF CYCLOOXYGENASE-2 [J].
KLEIN, T ;
NUSING, RM ;
PFEILSCHIFTER, J ;
ULLRICH, V .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (08) :1605-1610
[13]   Cyclooxygenase inhibition for postoperative analgesia [J].
McCrory, CR ;
Lindahl, SGE .
ANESTHESIA AND ANALGESIA, 2002, 95 (01) :169-176
[14]   BOLE OF SELECTINS IN LEUKOCYTE ADHESION TO PLATELETS AND ENDOTHELIUM [J].
MCEVER, RP .
PLATELET-DEPENDENT VASCULAR OCCLUSION, 1994, 714 :185-189
[15]   Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events [J].
Mukherjee, D .
BIOCHEMICAL PHARMACOLOGY, 2002, 63 (05) :817-821
[16]   Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor [J].
Riendeau, D ;
Percival, MD ;
Boyce, S ;
Brideau, C ;
Charleson, S ;
Cromlish, W ;
Ethier, D ;
Evans, J ;
Falgueyret, JP ;
FordHutchinson, AW ;
Gordon, R ;
Greig, G ;
Gresser, M ;
Guay, J ;
Kargman, S ;
Leger, S ;
Mancini, JA ;
ONeill, G ;
Ouellet, M ;
Rodger, IW ;
Therien, M ;
Wang, Z ;
Webb, JK ;
Wong, E ;
Xu, L ;
Young, RN ;
Zamboni, R ;
Prasit, P ;
Chan, CC .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 121 (01) :105-117
[17]  
Van Hecken A, 2000, J CLIN PHARMACOL, V40, P1109
[18]   Biomedicine: Back to an aspirin a day? [J].
Vane, JR .
SCIENCE, 2002, 296 (5567) :474-475